Dayton Oncology Report issue

Academic/Hospital Phase 2
Founded: Kettering OH United States (2006)

Organization Overview

First Clinical Trial
2007
NCT00602030
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

entinostat (1 trial)

erlotinib (tarceva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2